Company Filing History:

8 out of 2,198

Smithkline Beecham Corporation

patents

2 out of 281

Glaxo Wellcome Inc.

patents

Years Active: 2002-2006

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7129253 - Compounds (2006-10-31),

2. 7105529 - Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects (2006-09-12),

3. 7071217 - Substituted oxindole derivatives as tyrosine kinase inhibitors (2006-07-04),

4. 6964977 - Oxindole derivatives (2005-11-15),

5. 6815439 - Substituted aza-oxindole derivatives (2004-11-09),

6. 6624171 - Substituted aza-oxindole derivatives (2003-09-23),

7. 6541503 - Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors (2003-04-01),

8. 6387919 - Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors (2002-05-14),

9. 6369086 - Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors (2002-04-09),

10. 6350747 - 3-(anilinomethylene) oxindoles (2002-02-26),

Title: Innovations and Contributions of Inventor Lee Frederick Kuyper

Introduction

Lee Frederick Kuyper, based in Durham, NC, is a prolific inventor recognized for his advancements in pharmaceutical chemistry. With a total of 10 patents to his name, Kuyper has made significant contributions to the fields of protein tyrosine kinase and serine/threonine kinase inhibitors. His work plays a crucial role in developing therapies aimed at alleviating the side effects of chemotherapy and radiation therapy.

Latest Patents

Kuyper's recent innovations include compounds that exhibit protein tyrosine kinase and protein serine/threonine kinase inhibitory activity. One notable patent describes compounds of formula (I), where R1 to R8, A, D, X, Y, and Z are defined in the claims. These compounds represent a novel approach to treating diseases related to CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy. Another significant patent focuses on substituted oxindole derivatives, which serve as inhibitors for both protein tyrosine and serine/threonine kinases, presenting new therapeutic avenues for patients undergoing treatment.

Career Highlights

Throughout his career, Lee Frederick Kuyper has held key positions at leading organizations in the pharmaceutical industry. His tenure at SmithKline Beecham Corporation and Glaxo Wellcome Inc. highlights his extensive experience and commitment to drug development. His work has been instrumental in driving forward the frontiers of medicinal chemistry.

Collaborations

Kuyper has collaborated with notable professionals in his field, including Karen Elizabeth Lackey and Philip Anthony Harris. These collaborations have fostered a rich environment for innovation, resulting in groundbreaking discoveries and advancements within the realm of pharmacology.

Conclusion

Lee Frederick Kuyper's contributions as an inventor continue to shape the landscape of pharmaceutical development. His numerous patents reflect a deep commitment to addressing health challenges and enhancing treatment options for patients globally. Through his work, Kuyper exemplifies the spirit of innovation that drives progress in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com